0
     

Report Added
Report already added
Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027

Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027

The global neuromodulation market is valued at an estimated USD 6.0 billion in 2022 and is projected to reach USD 10.4 billion by 2027, at a CAGR of 11.8% during the forecast period. Market growth is driven by factors such as the growing incidence of rising incidence of Parkinson’s disease, high incidence of urine incontinence, extensive use of external neuromodulation in healthcare, low cost and ease of use are the major factors hampering the growth of this market.

“The internal neuromodulation segment accounted for the highest growth rate in the neuromodulation market, by product, during the forecast period”

The neuromodulation market is segmented into Internal neuromodulation and external neuromodulation. The internal neuromodulation is expected to register the highest growth rate during the forecast period. Factors such as the minimally invasive nature, reduced physical impact and improved quality of life are contributing to the growth of this segment.

“Deep Brain Stimulation segment accounted for the highest CAGR”

Based on type, the internal neuromodulation market is segmented into spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). Deep brain stimulation segment is expected to register highest growth rate during forecast period as DBS is a minimally invasive technique that allows the stimulation parameters to be changed to reduce side effects.

“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”

The global neuromodulation market is segmented into five regions - North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific region is expected to witness the highest growth in the neuromodulation market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of neurological disorders among senior population

The primary interviews conducted for this report can be categorized as follows:
•By Company Type: Tier 1 - 28%, Tier 2 - 42%, and Tier 3 - 30%
•By Designation: C-level - 30%, D-level - 34%, and Others - 36%
•By Region: North America - 46%, Europe - 25%, Asia Pacific - 18%, and the Rest of the World – 11%

Lists of Companies Profiled in the Report:
•Medtronic (Ireland)
•Boston Scientific Corporation (US)
•Abbott Laboratories (US)
•LivaNova (UK)
•NeuroPace (US)
•Neuronetics (US)
•Helius Medical Technologies (US)
•Renishaw (UK)
•GTX Medical (Netherlands)
•Bioinduction (UK)
•Bioness (US)
•Nevro Corporation (US)
•BlueWind Medical (Israel)
•Aleva Neurotherapeutics (Switzerland)
•GiMer Medical (Taiwan)
•NeuroSigma (US)
•BioWaveGo USA (US)
•Synapse Biomedical (US)
•Cardionomic (US)
•Theranica Bio-Electronics (Israel)
•MicroTransponder (US)
•Soterix Medical (US)
•Saluda Medical (US)
•Electrocore, Inc. (US)
•tVNS Technologies (Germany).

Research Coverage:
This report provides a detailed picture of the global neuromodulation market. It aims at estimating the size and future growth potential of the market across different segments, such as type, application and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall neuromodulation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
Table of Contents

1INTRODUCTION32
1.1STUDY OBJECTIVES32
1.2MARKET DEFINITION32
1.2.1INCLUSIONS AND EXCLUSIONS33
1.3MARKET SCOPE33
1.3.1NEUROMODULATION MARKET SEGMENTATION33
1.3.2YEARS CONSIDERED34
1.4CURRENCY CONSIDERED34
1.5STAKEHOLDERS34
1.6SUMMARY OF CHANGES35
2RESEARCH METHODOLOGY36
2.1RESEARCH DATA36
FIGURE 1RESEARCH DESIGN36
2.1.1SECONDARY DATA37
2.1.1.1Secondary sources38
2.1.2PRIMARY DATA38
2.1.2.1Key data from primary sources39
2.1.2.2Key industry insights40
TABLE 1BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS40
FIGURE 2BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION41
2.2MARKET SIZE ESTIMATION41
2.2.1BOTTOM-UP APPROACH42
FIGURE 3MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH42
FIGURE 4MARKET SIZE ESTIMATION: TOP-DOWN APPROACH43
FIGURE 5CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS43
2.3MARKET BREAKDOWN AND DATA TRIANGULATION44
FIGURE 6DATA TRIANGULATION METHODOLOGY44
2.4MARKET SHARE ANALYSIS45
2.5ASSUMPTIONS45
2.6RISK ASSESSMENT45
TABLE 2RISK ASSESSMENT: NEUROMODULATION MARKET45
2.7LIMITATIONS46
2.7.1METHODOLOGY-RELATED LIMITATIONS46
2.7.2SCOPE-RELATED LIMITATIONS46

3EXECUTIVE SUMMARY47
FIGURE 7NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)47
FIGURE 8INTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)48
FIGURE 9EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)48
FIGURE 10NEUROMODULATION MARKET: GEOGRAPHIC SNAPSHOT49
4PREMIUM INSIGHTS50
4.1NEUROMODULATION MARKET OVERVIEW50
FIGURE 11RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE GROWTH IN NEUROMODULATION MARKET50
4.2NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE & COUNTRY (2021)50
FIGURE 12INTERNAL NEUROMODULATION ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 202150
4.3GEOGRAPHIC GROWTH OPPORTUNITIES IN NEUROMODULATION MARKET51
FIGURE 13COUNTRIES IN ASIA PACIFIC TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD51
5MARKET OVERVIEW52
5.1INTRODUCTION52
5.2MARKET DYNAMICS52
FIGURE 14NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES52
5.2.1DRIVERS53
5.2.1.1Rising prevalence of neurological disorders and nerve injuries53
5.2.1.2Growing focus on neuromodulation & neurostimulation technologies53
5.2.1.3Expanding applications of neuromodulation54
TABLE 3INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS54
FIGURE 15RESEARCH PAPERS PUBLISHED (2011–2021)55
5.2.1.4Growing geriatric population and subsequent increase in prevalence of neurological disorders55
5.2.1.5Government support for research on neurological disorders56
FIGURE 16FUNDING FOR RESEARCH BY NIH (US)56
5.2.2RESTRAINTS57
5.2.2.1High cost of neuromodulation procedures57
5.2.3OPPORTUNITIES57
5.2.3.1Emerging economies57
FIGURE 17GROWTH IN CURRENT PER CAPITA HEALTHCARE EXPENDITURE, 2012–201957
5.2.4CHALLENGES58
5.2.4.1Stringent regulatory frameworks and time-consuming approval processes58
5.2.4.2Preference for drug therapies over neuromodulation products58
5.2.4.3Shortage of trained professionals58
5.2.4.4Product recalls58
TABLE 4MAJOR PRODUCT RECALLS59
5.3SCENARIO-BASED MARKET ASSESSMENT60
5.3.1NEUROMODULATION MARKET60
FIGURE 18PESSIMISTIC SCENARIO60
FIGURE 19OPTIMISTIC SCENARIO60
FIGURE 20REALISTIC SCENARIO61
5.4VALUE CHAIN ANALYSIS61
FIGURE 21VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE62
5.4.1RESEARCH & DEVELOPMENT62
5.4.2MANUFACTURING & ASSEMBLY62
5.4.3DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES62
5.5SUPPLY CHAIN ANALYSIS63
FIGURE 22DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES63
5.6TECHNOLOGY ANALYSIS64
5.7PORTER’S FIVE FORCES ANALYSIS64
5.7.1THREAT FROM NEW ENTRANTS65
5.7.2INTENSITY OF COMPETITIVE RIVALRY65
5.7.3BARGAINING POWER OF BUYERS65
5.7.4BARGAINING POWER OF SUPPLIERS65
5.7.5THREAT FROM SUBSTITUTES65
5.8KEY STAKEHOLDERS AND BUYING CRITERIA66
5.8.1KEY STAKEHOLDERS IN THE BUYING PROCESS66
FIGURE 23INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS, BY TECHNOLOGY66
TABLE 5INFLUENCE OF STAKEHOLDERS ON THE BUYING PROCESS FOR THE TOP 3 TECHNOLOGIES (%)66
5.8.2BUYING CRITERIA66
FIGURE 24KEY BUYING CRITERIA FOR TOP 2 END USERS66
TABLE 6KEY BUYING CRITERIA, BY END USER67
5.9REGULATORY LANDSCAPE67
TABLE 7INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION67
5.9.1BY REGION68
5.9.1.1North America68
5.9.1.2Europe68
5.9.1.3Asia Pacific69
5.9.1.3.1India69
5.9.1.3.2China69
5.10PATENT ANALYSIS69

5.11KEY CONFERENCES AND EVENTS IN 202270
TABLE 8LIST OF CONFERENCES & EVENTS70
5.12PRICING ANALYSIS71
TABLE 9PRICE RANGE FOR NEUROMODULATION DEVICES AND PROCEDURES71
5.13TRADE ANALYSIS72
TABLE 10IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)72
TABLE 11EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2016–2020 (USD MILLION)72
5.14ECOSYSTEM ANALYSIS73
5.14.1ROLE IN ECOSYSTEM73
5.14.2KEY PLAYERS IN THE NEUROMODULATION MARKET74
5.15TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES74
6NEUROMODULATION MARKET, BY TYPE75
6.1INTRODUCTION76
TABLE 12NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)76
6.2INTERNAL NEUROMODULATION76
TABLE 13INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)77
TABLE 14INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)77
TABLE 15NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 16EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)78
TABLE 17ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)78
TABLE 18REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)78
6.2.1SPINAL CORD STIMULATION79
6.2.1.1Growing incidence of spinal cord injuries to support market growth79
TABLE 19SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)80
TABLE 20SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)80
TABLE 21NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 22EUROPE: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 23ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 24REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)81
6.2.2DEEP BRAIN STIMULATION82
6.2.2.1DBS allows stimulation parameters to be changed to reduce side effects82
TABLE 25DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)82
TABLE 26DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)83
TABLE 27NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 28EUROPE: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 29ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)84
TABLE 30REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)84
6.2.3VAGUS NERVE STIMULATION84
6.2.3.1Non-invasive vagus nerve stimulation does not require surgical implantation—a key benefit84
TABLE 31VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)85
TABLE 32VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)85
TABLE 33NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 34EUROPE: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 35ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)86
TABLE 36REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)86
6.2.4SACRAL NERVE STIMULATION87
6.2.4.1Widening scope of sacral nerve stimulation to drive growth87
TABLE 37SACRAL NERVE STIMULATION DEVICES OFFERED87
TABLE 38SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)87
TABLE 39SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)88
TABLE 40NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 41EUROPE: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)88
TABLE 42ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 43REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)89
6.2.5GASTRIC ELECTRICAL STIMULATION89
6.2.5.1Growing number of people suffering from severe GERD and gastroparesis to fuel market growth89
TABLE 44GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)90
TABLE 45GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)90
TABLE 46NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 47EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 48ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 49REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)91
6.3EXTERNAL NEUROMODULATION92
TABLE 50EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)92
TABLE 51EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)92
TABLE 52NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 53EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 54ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 55REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)93
6.3.1TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION94
6.3.1.1Extensive use in healthcare, low cost, and ease of use to favor market growth94
TABLE 56TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)94
TABLE 57TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)95
TABLE 58NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 59EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 60ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)96
TABLE 61REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)96
6.3.2TRANSCRANIAL MAGNETIC STIMULATION96
6.3.2.1Minimal patient discomfort associated with TMS supports demand96
TABLE 62TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)97
TABLE 63TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)97
TABLE 64NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 65EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)98
TABLE 66ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)98
TABLE 67REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)98

6.3.3RESPIRATORY ELECTRICAL STIMULATION99
6.3.3.1High treatment efficacy to fuel market growth99
TABLE 68RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)99
TABLE 69RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (UNITS)99
TABLE 70NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)100
TABLE 71EUROPE: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)100
TABLE 72ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)100
TABLE 73REST OF THE WORLD: RESPIRATORY ELECTRICAL STIMULATION MARKET, BY REGION, 2020–2027 (USD MILLION)101
7NEUROMODULATION MARKET, BY APPLICATION102
7.1INTRODUCTION103
7.2SPINAL CORD STIMULATION MARKET, BY APPLICATION103
TABLE 74SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)103
7.2.1CHRONIC PAIN103
7.2.1.1High incidence of chronic pain supports market growth103
TABLE 75SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2020–2027 (USD MILLION)103
7.2.2FAILED BACK SURGERY SYNDROME104
7.2.2.1Growing incidence of FBSS due to rising number of surgeries each year to drive demand for stimulation technologies104
TABLE 76SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2020–2027 (USD MILLION)104
7.2.3ISCHEMIA104
7.2.3.1High effectiveness of neuromodulation for ischemia treatment to support market growth104
TABLE 77SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2020–2027 (USD MILLION)105
7.3DEEP BRAIN STIMULATION MARKET, BY APPLICATION105
TABLE 78DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)105
7.3.1PARKINSON’S DISEASE105
7.3.1.1Rising incidence of Parkinson’s disease and growing R&D activity in this area to drive growth105
TABLE 79DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)106
7.3.2TREMORS106
7.3.2.1High efficacy of DBS in treating tremors boosts demand106
TABLE 80DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2020–2027 (USD MILLION)106

7.3.3DEPRESSION107
7.3.3.1Lack of evidence of efficacy of DBS for depression treatment to limit market growth107
TABLE 81DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)107
7.3.4OTHER DBS APPLICATIONS107
TABLE 82DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)108
7.4SACRAL NERVE STIMULATION MARKET, BY APPLICATION108
TABLE 83SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)108
7.4.1URINE INCONTINENCE108
7.4.1.1High incidence of urine incontinence offers growth opportunities108
TABLE 84SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)109
7.4.2FECAL INCONTINENCE109
7.4.2.1Reduced symptom recurrence supports use of SNS in fecal incontinence treatment109
TABLE 85SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2020–2027 (USD MILLION)109
7.5VAGUS NERVE STIMULATION MARKET, BY APPLICATION110
TABLE 86VAGUS NERVE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)110
7.5.1EPILEPSY110
7.5.1.1Advantages associated with VNS in epilepsy treatment to propel market110
TABLE 87VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2020–2027 (USD MILLION)110
7.5.2OTHER VNS APPLICATIONS110
TABLE 88VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)111
7.6GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION111
TABLE 89GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)111
7.6.1GASTROPARESIS111
7.6.1.1GES treatment reduces hospitalizations for patients affected by gastroparesis111
TABLE 90GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2020–2027 (USD MILLION)112
7.6.2OBESITY112
7.6.2.1Risks associated with gastric bypass to increase preference for GES112
TABLE 91GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION)112
7.7TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION113
TABLE 92TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)113

7.7.1TREATMENT-RESISTANT DEPRESSION113
7.7.1.1TENS induces relaxed state in patients suffering from treatment-resistant depression113
TABLE 93TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2020–2027 (USD MILLION)113
7.7.2OTHER TENS APPLICATIONS113
TABLE 94TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)114
7.8TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION114
TABLE 95TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)114
7.8.1DEPRESSION114
7.8.1.1Increased acceptance among patients to drive demand for TMS114
TABLE 96TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2020–2027 (USD MILLION)115
7.8.2MIGRAINE115
7.8.2.1High prevalence of migraine to support market growth115
TABLE 97TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2020–2027 (USD MILLION)115
7.9RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION116
7.9.1SPINAL CORD INJURY116
7.9.1.1Rising incidence of spinal cord injuries ensures sustained demand for RES116
TABLE 98RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2020–2027 (USD MILLION)116
8NEUROMODULATION MARKET, BY REGION117
8.1INTRODUCTION118
TABLE 99NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)118
8.2NORTH AMERICA118
FIGURE 25NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT119
TABLE 100NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)120
TABLE 101NORTH AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)120
TABLE 102NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)120
TABLE 103NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)121
TABLE 104NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)121
TABLE 105NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)121
TABLE 106NORTH AMERICA: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)122
TABLE 107NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)122
TABLE 108NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)122
TABLE 109NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)122
TABLE 110NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)123
8.2.1US123
8.2.1.1Large number of prominent players makes US the largest market123
TABLE 111US: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)124
TABLE 112US: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)124
TABLE 113US: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)125
8.2.2CANADA125
8.2.2.1Rising healthcare expenditure and increasing disease prevalence will drive demand for neurostimulation125
TABLE 114NEUROLOGICAL CONDITIONS PREVALENT IN CANADA126
TABLE 115CANADA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)126
TABLE 116CANADA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)127
TABLE 117CANADA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)127
8.3EUROPE127
TABLE 118EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)128
TABLE 119EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)128
TABLE 120EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)128
TABLE 121EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)129
TABLE 122EUROPE: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)129
TABLE 123EUROPE: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)129
TABLE 124EUROPE: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)130
TABLE 125EUROPE: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)130
TABLE 126EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)130
TABLE 127EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)130
TABLE 128EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)131
8.3.1GERMANY131
8.3.1.1Favorable government initiatives ensure strong market growth in Germany131
TABLE 129GERMANY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)132
TABLE 130GERMANY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)132
TABLE 131GERMANY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)132
8.3.2UK133
8.3.2.1High public- and private-sector investments fuel market growth133
TABLE 132UK: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)134
TABLE 133UK: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)134
TABLE 134UK: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)134
8.3.3FRANCE135
8.3.3.1Availability of insurance and favorable healthcare reforms contribute to growth135
TABLE 135FRANCE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)135
TABLE 136FRANCE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)135
TABLE 137FRANCE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)136
8.3.4ITALY136
8.3.4.1Easy access to healthcare services makes Italy a lucrative market136
TABLE 138ITALY: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)136
TABLE 139ITALY: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)137
TABLE 140ITALY: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)137
8.3.5SPAIN137
8.3.5.1Growing government initiatives may support market growth in Spain137
TABLE 141SPAIN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)138
TABLE 142SPAIN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)138
TABLE 143SPAIN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)138
8.3.6REST OF EUROPE138
TABLE 144PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2019 VS. 2050139
TABLE 145REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)139
TABLE 146REST OF EUROPE: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)140
TABLE 147REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)140
8.4ASIA PACIFIC140
FIGURE 26ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT141
TABLE 148ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)141
TABLE 149ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)142
TABLE 150ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)142
TABLE 151ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)142
TABLE 152ASIA PACIFIC: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)143
TABLE 153ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)143
TABLE 154ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)143
TABLE 155ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)144
TABLE 156ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)144
TABLE 157ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)144
TABLE 158ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)144
8.4.1JAPAN145
8.4.1.1Japan dominates the APAC market for neuromodulation145
TABLE 159JAPAN: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)145
TABLE 160JAPAN: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)146
TABLE 161JAPAN: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)146
8.4.2CHINA146
8.4.2.1Growing geriatric population will favor market growth in China146
TABLE 162CHINA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)147
TABLE 163CHINA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)147
TABLE 164CHINA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)147
8.4.3INDIA148
8.4.3.1Improvements in healthcare infrastructure in the country will support market148
TABLE 165INDIA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)148
TABLE 166INDIA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)148
TABLE 167INDIA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)149

8.4.4REST OF ASIA PACIFIC149
TABLE 168REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)150
TABLE 169REST OF ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)150
TABLE 170REST OF ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)150
8.5REST OF THE WORLD151
TABLE 171REST OF THE WORLD: NEUROMODULATION MARKET, BY REGION, 2020–2027 (USD MILLION)151
TABLE 172REST OF THE WORLD: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)151
TABLE 173REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)152
TABLE 174REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)152
TABLE 175REST OF THE WORLD: SPINAL CORD STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)152
TABLE 176REST OF THE WORLD: DEEP BRAIN STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)153
TABLE 177REST OF THE WORLD: SACRAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)153
TABLE 178REST OF THE WORLD: VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)153
TABLE 179REST OF THE WORLD: GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)154
TABLE 180REST OF THE WORLD: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)154
TABLE 181REST OF THE WORLD: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)154
8.5.1LATIN AMERICA154
8.5.1.1Latin America holds largest share of neuromodulation market in RoW154
TABLE 182LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)155
TABLE 183LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)155
TABLE 184LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)155
8.5.2MIDDLE EAST & AFRICA156
8.5.2.1High cost of neuromodulation to hamper market growth156
TABLE 185MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)156
TABLE 186MIDDLE EAST & AFRICA: INTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)156
TABLE 187MIDDLE EAST & AFRICA: EXTERNAL NEUROMODULATION MARKET, BY TYPE, 2020–2027 (USD MILLION)157

9COMPETITIVE LANDSCAPE158
9.1OVERVIEW158
9.2KEY PLAYER STRATEGIES/RIGHT TO WIN158
TABLE 188OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS158
9.3REVENUE SHARE ANALYSIS159
FIGURE 27REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET159
9.4MARKET SHARE ANALYSIS160
TABLE 189NEUROMODULATION MARKET: DEGREE OF COMPETITION160
9.5COMPANY EVALUATION MATRIX161
9.5.1STARS161
9.5.2EMERGING LEADERS161
9.5.3PERVASIVE PLAYERS161
9.5.4PARTICIPANTS161
FIGURE 28COMPANY EVALUATION MATRIX: NEUROMODULATION MARKET162
9.6COMPANY EVALUATION MATRIX FOR SMES/START-UPS162
9.6.1PROGRESSIVE COMPANIES162
9.6.2STARTING BLOCKS162
9.6.3RESPONSIVE COMPANIES163
9.6.4DYNAMIC COMPANIES163
FIGURE 29COMPANY EVALUATION MATRIX FOR SMES/START-UPS: NEUROMODULATION MARKET163
9.7COMPANY FOOTPRINT ANALYSIS164
TABLE 190OVERALL FOOTPRINT OF COMPANIES164
TABLE 191REGIONAL FOOTPRINT OF COMPANIES165
TABLE 192TYPE FOOTPRINT OF COMPANIES166
9.8COMPETITIVE BENCHMARKING167
TABLE 193NEUROMODULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES167
9.9COMPETITIVE SCENARIO167
9.9.1PRODUCT LAUNCHES & APPROVALS167
TABLE 194KEY PRODUCT LAUNCHES & APPROVALS167
9.9.2DEALS168
TABLE 195KEY DEALS168
9.9.3OTHER DEVELOPMENTS169
TABLE 196OTHER KEY DEVELOPMENTS169

10COMPANY PROFILES170
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1KEY PLAYERS170
10.1.1MEDTRONIC PLC170
TABLE 197MEDTRONIC PLC: BUSINESS OVERVIEW170
FIGURE 30MEDTRONIC PLC: COMPANY SNAPSHOT (2021)171
10.1.2BOSTON SCIENTIFIC CORPORATION175
TABLE 198BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW175
FIGURE 31BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2021)176
10.1.3ABBOTT LABORATORIES179
TABLE 199ABBOTT LABORATORIES: BUSINESS OVERVIEW179
FIGURE 32ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)180
10.1.4LIVANOVA PLC182
TABLE 200LIVANOVA PLC: BUSINESS OVERVIEW182
FIGURE 33LIVANOVA PLC: COMPANY SNAPSHOT (2021)183
10.1.5NEVRO CORPORATION185
TABLE 201NEVRO CORPORATION: BUSINESS OVERVIEW185
FIGURE 34NEVRO CORPORATION: COMPANY SNAPSHOT (2021)185
10.1.6NEUROSIGMA, INC.187
TABLE 202NEUROSIGMA, INC.: BUSINESS OVERVIEW187
10.1.7NEUROPACE, INC.189
TABLE 203NEUROPACE, INC.: BUSINESS OVERVIEW189
FIGURE 35NEUROPACE, INC.: COMPANY SNAPSHOT (2021)189
10.1.8SOTERIX MEDICAL INC.192
TABLE 204SOTERIX MEDICAL INC.: BUSINESS OVERVIEW192
10.1.9SYNAPSE BIOMEDICAL INC.194
TABLE 205SYNAPSE BIOMEDICAL INC.: BUSINESS OVERVIEW194
10.1.10ALEVA NEUROTHERAPEUTICS SA195
TABLE 206ALEVA NEUROTHERAPEUTICS SA: BUSINESS OVERVIEW195
10.1.11THERANICA BIO-ELECTRONICS LTD.196
TABLE 207THERANICA BIO-ELECTRONICS LTD.: BUSINESS OVERVIEW196
10.1.12NEURONETICS197
TABLE 208NEURONETICS: BUSINESS OVERVIEW197
FIGURE 36NEURONETICS: COMPANY SNAPSHOT (2021)198
10.1.13BIONESS200
TABLE 209BIONESS: BUSINESS OVERVIEW200
10.1.14BIOINDUCTION201
TABLE 210BIOINDUCTION: BUSINESS OVERVIEW201

10.2OTHER PLAYERS202
10.2.1GIMER MEDICAL202
10.2.2GTX MEDICAL202
10.2.3HELIUS MEDICAL TECHNOLOGIES203
10.2.4MICROTRANSPONDER203
10.2.5BLUEWIND MEDICAL204
10.2.6ELECTROCORE, INC.204
10.2.7RENISHAW PLC205
10.2.8TVNS TECHNOLOGIES GMBH205
10.2.9BIOWAVEGO USA206
10.2.10CARDIONOMIC, INC.206
10.2.11SALUDA MEDICAL PTY LTD.206
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11APPENDIX207
11.1DISCUSSION GUIDE207
11.2KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL212
11.3AVAILABLE CUSTOMIZATIONS214
11.4RELATED REPORTS214
11.5AUTHOR DETAILS215

Report Title: Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW